Key Documents

View All Documentation

C6643

Clofibrate

Name: Clofibrate
Brand: SIGMA

liquid

Synonym(s):

2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester, Ethyl 2-(4-chlorophenoxy)-2-methylpropionate, Ethyl 2-(4-chlorophenoxy)isobutyrate

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₂H₁₅ClO₃

CAS Number:

637-07-0

Molecular Weight:

242.70

UNSPSC Code:

12352200

NACRES:

NA.77

PubChem Substance ID:

24278085

EC Number:

211-277-4

Beilstein/REAXYS Number:

1913459

MDL number:

MFCD00000615

Form:

liquid

Quality level:

200

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

form

liquid

Quality Level

200

color

clear colorless

density

1.14 g/mL at 25 °C (lit.)

originator

Wyeth

storage temp.

2-8°C

SMILES string

CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1

InChI

1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3

InChI key

KNHUKKLJHYUCFP-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)
mouse ... Ppara(19013)

Description

Application

Clofibrate has been used:

as a quinolinate phosphoribosyltransferase (QPRT) agonist to study its effects on hepatitis C virus (HCV) infection
as peroxisome proliferated activated receptor (PPAR) agonist to study its effects on autophagy in rat liver cells
as a hepatotoxicant to study its effects on gene expression in primary rat hepatocytes

Biochem/physiol Actions

Clofibrate is a peroxisome proliferated activated receptor α (PPARα) agonist. It is a fibric acid derivative and has a therapeutic effect on hypertriglyceridemia and hyperlipoproteinemia type III. Clofibrate participates in lowering the very-low-density lipoprotein (VLDL) and cholesterol levels in hyperlipoproteinemia type III patients. It facilitates the decrease of total serum bilirubin concentration in Gilbert′s syndrome.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Still not finding the right product?

Explore all of our products under Clofibrate

pictograms

GHS05,GHS07

signalword

Danger

hcodes

H302,H315,H318,H335

pcodes

P261 - P264 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

10 - Combustible liquids

wgk

WGK 3

flash_point_f

235.4 °F - closed cup

flash_point_c

113 °C - closed cup

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Discover Bioactive Small Molecules for Lipid Signaling Research

Cholesterol Biosynthesis Regulation

Cholesterol synthesis regulation by dietary levels, LDL receptors control lipid-rich LDL particle transport in cells.

胆固醇生物合成调节

肝脏中胆固醇的合成量由饮食中的胆固醇水平来严格调节。LDL受体调节富含脂质的低密度脂蛋白（LDL）颗粒的细胞转运。

A novel transcriptomics based in vitro method to compare and predict hepatotoxicity based on mode of action.

K Nadira De Abrew et al.

Toxicology, 328, 29-39 (2014-12-06)

High-content data have the potential to inform mechanism of action for toxicants. However, most data to support this notion have been generated in vivo. Because many cell lines and primary cells maintain a differentiated cell phenotype, it is possible that

Drug treatment of lipid disorders.

R H Knopp

The New England journal of medicine, 341(7), 498-511 (1999-08-12)

Prenatal PPARα activation by clofibrate increases subcutaneous fat browning in male C57BL/6J mice fed a high-fat diet during adulthood.

Szu-Han Chen et al.

PloS one, 12(11), e0187507-e0187507 (2017-11-03)

We tested the hypothesis that prenatal administration of PPARα agonist clofibrate may permanently increase browning capacity of developing white adipose tissue (WAT). Pregnant C57BL/6J mice were fed a basal diet, without (C) or with 0.5% clofibrate (CF, a PPARα agonist)

View All Related Papers

Global Trade Item Number

SKU	GTIN
C6643-1G	04061838172259
C6643-250MG	04061838172266
C6643-5G	04061838162854
C6643-10G	04061833511428

Key Documents

Clofibrate

liquid

Select a Size

About This Item

form

Quality Level

color

density

originator

storage temp.

SMILES string

InChI

InChI key

Gene Information

Application

Biochem/physiol Actions

Features and Benefits

Packaging

Still not finding the right product?

Safety Information

pictograms

signalword

hcodes

pcodes

Hazard Classifications

target_organs

Storage Class

wgk

flash_point_f

flash_point_c

ppe

Documentation

Certificates of Analysis (COA)

Already Own This Product?

Protocols and Articles

Articles

Peer Reviewed Papers

Global Trade Item Number